This site is intended for healthcare professionals
Hands with atopic dermatitis
Expert podcasts

Grappling with hand and foot atopic dermatitis

Last updated: 23rd Jun 2024
Published:23rd Jun 2024

Dr Linda Stein Gold and Dr Jonathan Silverberg discuss atopic dermatitis of the hands and feet, including its multidimensional burden on quality of life.

Many people with hand and foot atopic dermatitis feel frustrated by recurrent itching and, in the case of hand dermatitis, feel embarrassed by the appearance of their hands

Thank you for answering the questions. Your input will help us improve Medthority.

Listen to the hand and foot dermatitis podcasts here.

Before you continue, please help us improve by answering these questions.

Before you continue, please help us improve by answering these questions.

A female patient, 34 years of age, presents with lesions on her hands that are typically associated with atopic dermatitis of the hands.

A female patient, 34 years of age, presents with lesions on her hands that are typically associated with atopic dermatitis of the hands.

1. Which types of lesions suggestive of a diagnosis of atopic dermatitis are likely to be present on this patient's hands?
2. If you conclude this patient has atopic dermatitis with involvement of the hands and feet, what would you consider is important to ask them for more information on?
3. What, according to Professor Jonathan Silverberg, is an advantage of structured assessments over open-ended questions?
4. For which of the following reasons would you perform a patch test in this patient?
5. For what purpose would you use the Investigator’s Global Assessment in this patient?
How confident would you be to manage a patient case like this?

Episode 1: Getting to grips with atopic dermatitis of the hands and feet: What is it, and what does it mean for patients? 

 

 

Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the epidemiology, clinical presentation and classification of atopic dermatitis of the hands and feet. What impact does it have on patients’ quality of life and how can we effectively measure this?

Episode 2: First-hand experience: Practical insights on the diagnosis and assessment of atopic dermatitis of the hands and feet

 

Dr Linda Stein Gold and Dr Jonathan Silverberg consider the challenges associated with the diagnosis of atopic dermatitis of the hands and feet and tools for assessing disease severity in clinical practice. What tools are available and how can they be used in the clinic?

Meet the experts

Dr Linda Stein Gold

Dr Linda Stein Gold is Director of Dermatology Clinical Research for the Henry Ford Health System in Detroit, Michigan, and Division Head of Dermatology for the Henry Ford Health System in West Bloomfield, Michigan, USA. Her recent research has focused on treatments for atopic dermatitis, rosacea, acne, psoriasis, seborrheic dermatitis, alopecia areata and actinic keratoses.

Disclosures: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi.

Dr Jonathan Silverberg

Dr Jonathan Silverberg is a Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, USA. He is the Director of Clinical Research and Contact Dermatitis. Dr Silverberg’s area of clinical subspecialty is inflammatory skin disease, particularly atopic and contact dermatitis. He is also a national expert in allergy patch testing, phototesting and photopatch testing. Dr Silverberg’s research interests include the epidemiology of chronic and infectious diseases.

Disclosures: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer. 

More information at ADVENTprogram.com

Developed by EPG Health, in collaboration with Sanofi and Regeneron, with content provided by Sanofi and Regeneron. 
 
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals. 
 
These podcasts are intended for healthcare professionals only. The speakers are being compensated and/or receiving honorarium from Sanofi and Regeneron in connection with this programme. 
 
The content contained in this programme was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. 
 
© 2024 Sanofi and Regeneron All rights reserved. MAT-US-2405450 v1.0 - P Exp Date: 07/08/2026
 
Sanofi and Regeneron are committed to providing resources to advance knowledge in areas of unmet medical need among patients with inflammatory and immunologic diseases.